Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

At ASCO 2025, Bayer announced new data from recent clinical trials that highlight significant advancements in both prostate ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease ...

Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis (RRP), a rare ...

In another sign of increased regulatory scrutiny of vaccines in the US, Health and Human Services (HHS) Secretary Robert F ...

In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life ...